Home/Filings/4/0001610717-24-000516
4//SEC Filing

Patel Sushil 4

Accession 0001610717-24-000516

CIK 0001628171other

Filed

Nov 3, 7:00 PM ET

Accepted

Nov 4, 4:05 PM ET

Size

8.6 KB

Accession

0001610717-24-000516

Insider Transaction Report

Form 4
Period: 2024-10-31
Patel Sushil
Director
Transactions
  • Exercise/Conversion

    Common Stock

    2024-10-31$24.84/sh+5,000$124,20024,948 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2024-10-315,00013,400 total
    Exercise: $24.84From: 2024-06-08Exp: 2033-06-07Common Stock (5,000 underlying)
  • Sale

    Common Stock

    2024-10-31$54.14/sh5,000$270,71519,948 total
Footnotes (3)
  • [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on September 7, 2023.
  • [F2]Includes 7,748 restricted stock units.
  • [F3]The transaction was executed in multiple trades in prices ranging from $54.00 to $54.30, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Documents

1 file

Issuer

Revolution Medicines, Inc.

CIK 0001628171

Entity typeother

Related Parties

1
  • filerCIK 0001860609

Filing Metadata

Form type
4
Filed
Nov 3, 7:00 PM ET
Accepted
Nov 4, 4:05 PM ET
Size
8.6 KB